Download PDF
CC BY 4.0 · Glob Med Genet 2022; 09(03): 242-246
DOI: 10.1055/s-0042-1756663
Review Article

Role of Molecular Targeted Therapeutic Drugs in Treatment of Oral Squamous Cell Carcinoma: Development and Current Strategies—A Review Article

Himanshu Singh
1   Department of Oral and Maxillofacial Pathology and Oral Microbiology, Index Institute of Dental Sciences, Indore, Madhya Pradesh, India
,
Vedant Patel
2   Department of Prosthodontics and Crown & Bridge, Index Institute of Dental Sciences, Indore, Madhya Pradesh, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Because of active advancement in the field of biomedicine, people have in-depth knowledge of biological nature of malignant tumors and are able to recognized the overexpression of different molecules such as vascular endothelial growth factor receptor, cyclin-dependent kinase, and programmed cell death receptor. Presently, various targeted therapeutic drugs are used in different clinical trials in those patients suffering from oral squamous cell carcinoma. In this review, we converse about the various targeted therapeutic drugs and their advancement in the treatment of oral squamous cell carcinoma. This review scrutinizes the existing documentation in the literature related to the targeted therapies for oral squamous cell carcinoma. English language articles were searched in various databases such as PubMed, Scopus, Science Direct, and Google Scholar. The keywords used for searching are “oral squamous cell carcinoma,” “targeted therapy,” and “therapeutic drugs.”

Keywords

oral squamous cell carcinoma - therapeutic drugs - targeted therapy


Publication History

Article published online:
19 September 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Tshering Vogel DW, Zbaeren P, Thoeny HC. Cancer of the oral cavity and oropharynx. Cancer Imaging 2010; 10: 62-72
    CrossrefPubMedGoogle Scholar
  • 2 Ghantous Y, Abu Elnaaj I. Global incidence and risk factors of oral cancer. Harefuah 2017; 156 (10) 645-649
    PubMedGoogle Scholar
  • 3 Singhvi HR, Malik A, Chaturvedi P. The role of chronic mucosal trauma in oral cancer: a review of literature. Indian J Med Paediatr Oncol 2017; 38 (01) 44-50
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Ling D, Nong X. Advances in targeted therapy for oral and maxillofacial head and neck squamous cell carcinoma. [J] J Oral Maxillofac Surg 2009; 19 (02) 145-148
    Google Scholar
  • 5 Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4 (05) 336-347
    CrossrefPubMedGoogle Scholar
  • 6 Dong H, Strome SE, Salomao DR. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8 (08) 793-800
    CrossrefPubMedGoogle Scholar
  • 7 Grzywnowicz M, Giannopoulos K. The role of receptor programmed death-1 and its ligands in immune system and tumors. Acta Haematol Pol 2012; 43: 132-145
    Google Scholar
  • 8 Mishra A. PD-1/PD-L1 biology and immunotherapy in HPV-positive oral cancers. Future Oncol 2017; 13 (22) 1907-1909
    CrossrefPubMedGoogle Scholar
  • 9 Maruse Y, Kawano S, Jinno T. et al. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma. Int J Oral Maxillofac Implants 2018; 47 (07) 836-845
    CrossrefPubMedGoogle Scholar
  • 10 Mann JE, Hoesli R, Michmerhuizen NL. et al. Surveilling the potential for precision medicine-driven PD-1/PD-L1-targeted therapy in HNSCC. J Cancer 2017; 8 (03) 332-344
    CrossrefPubMedGoogle Scholar
  • 11 Pembrolizumab N. Has antitumor activity in advanced head and neck cancer. Cancer Discov 2016; 6 (07) 693
    CrossrefGoogle Scholar
  • 12 Roskoski Jr R. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacol Res 2019; 139: 471-488
    CrossrefPubMedGoogle Scholar
  • 13 Chohan TA, Qayyum A, Rehman K, Tariq M, Akash MSH. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers. Biomed Pharmacother 2018; 107: 1326-1341
    CrossrefPubMedGoogle Scholar
  • 14 Chang JT, Wang HM, Chang KW. et al. Identification of differentially expressed genes in oral squamous cell carcinoma (OSCC): overexpression of NPM, CDK1 and NDRG1 and underexpression of CHES1. Int J Cancer 2005; 114 (06) 942-949
    CrossrefPubMedGoogle Scholar
  • 15 Chen X, Zhang FH, Chen QE. et al. The clinical significance of CDK1 expression in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2015; 20 (01) e7-e12
    CrossrefPubMedGoogle Scholar
  • 16 Sánchez-Martínez C, Gelbert LM, Lallena MJ, de Dios A. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. Bioorg Med Chem Lett 2015; 25 (17) 3420-3435
    CrossrefPubMedGoogle Scholar
  • 17 Mihara M, Shintani S, Nakashiro K, Hamakawa H. Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells. Oral Oncol 2003; 39 (01) 49-55
    CrossrefPubMedGoogle Scholar
  • 18 Pai A, Jayashree BS. Computational Approach for the design of flavone based CDK2/CyclinA inhibitors: a simulation study employing pharmacophore based 3D QSAR. Research J Pharm Tech 2019; 12 (05) 2299-2303
    CrossrefGoogle Scholar
  • 19 Okada Y, Ueno H, Katagiri M. et al. Experimental study of antiangiogenic gene therapy targeting VEGF in oral cancer. Odontology 2010; 98 (01) 52-59
    CrossrefPubMedGoogle Scholar
  • 20 Stîngă AC, Mărgăritescu O, Stîngă AS. et al. VEGFR1 and VEGFR2 immunohistochemical expression in oral squamous cell carcinoma: a morphometric study. Rom J Morphol Embryol 2011; 52 (04) 1269-1275
    PubMedGoogle Scholar
  • 21 Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36 (02) 127-137
    CrossrefPubMedGoogle Scholar
  • 22 Fury MG, Xiao H, Sherman EJ. et al. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head Neck 2016; 38 (Suppl. 01) E566-E570
    CrossrefPubMedGoogle Scholar
  • 23 Ibrahim N, Yu Y, Walsh WR, Yang JL. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncol Rep 2012; 27 (05) 1303-1311
    PubMedGoogle Scholar
  • 24 Hsu FT, Chang B, Chiang IT, Wu TH, Hwang JJ. Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells. In Vivo 2014; 28 (05) 925-933
    PubMedGoogle Scholar
  • 25 Fathima MZ, Shanmugarajan TS, Kumar SS, Yadav BVVN. Comparative in silico docking studies of Hinokitiol with sorafenib and nilotinib against proto-oncogene tyrosine-protein kinase (ABL1) and mitogen-activated protein kinase (MAPK) to target hepatocellular carcinoma. Research J. Pharm. and Tech. 2017; 10 (01) 257-262
    CrossrefGoogle Scholar
  • 26 Zhang Y, Xue D, Wang X, Lu M, Gao B, Qiao X. Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways. Mol Med Rep 2014; 9 (01) 83-90
    CrossrefPubMedGoogle Scholar
  • 27 Yadav A, Kumar B, Teknos TN, Kumar P. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther 2011; 10 (07) 1241-1251
    CrossrefPubMedGoogle Scholar
  • 28 Möckelmann N, Rieckmann T, Busch CJ. et al. Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells. Oncotarget 2016; 7 (17) 23542-23551
    CrossrefPubMedGoogle Scholar
  • 29 Laban S, Steinmeister L, Gleißner L. et al. Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation. Radiother Oncol 2013; 109 (02) 286-292
    CrossrefPubMedGoogle Scholar
  • 30 Papadimitrakopoulou VA, Frank SJ, Cohen EW. et al. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck 2016; 38 (03) 439-447
    CrossrefPubMedGoogle Scholar
  • 31 Bozec A, Sudaka A, Toussan N, Fischel JL, Etienne-Grimaldi MC, Milano G. Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model. Ann Oncol 2009; 20 (10) 1703-1707
    CrossrefPubMedGoogle Scholar
  • 32 Machiels JP, Henry S, Zanetta S. et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010; 28 (01) 21-28
    CrossrefPubMedGoogle Scholar
  • 33 Shakila Banu S, Krishnamoorthy G, Senthamarai R, Mohamed Jaabir MS. Synthesis, spectral characterization and anticancer activity of novel pyrimidine derivatives. Research J Pharm Tech 2020; 13 (12) 6243-6247
    CrossrefGoogle Scholar
  • 34 Lyu J, Song H, Tian Z, Miao Y, Ren G, Guo W. Predictive value of pAKT/PTEN expression in oral squamous cell carcinoma treated with cetuximab-based chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol 2016; 121 (01) 67-72
    CrossrefPubMedGoogle Scholar
  • 35 Liao YM, Kim C, Yen Y. Mammalian target of rapamycin and head and neck squamous cell carcinoma. Head Neck Oncol 2011; 3 (01) 22-25
    CrossrefPubMedGoogle Scholar
  • 36 Mohamed MA, Elkhateeb WA, Taha MA, Daba GM. New strategies in optimization of rapamycin production by streptomyces hygroscopicus ATCC 29253. Research J Pharm Tech 2019; 12 (09) 4197-4204
    CrossrefGoogle Scholar
  • 37 Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett 2012; 319 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 38 Bauman JE, Arias-Pulido H, Lee SJ. et al. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol 2013; 49 (05) 461-467
    CrossrefPubMedGoogle Scholar
  • 39 Lane HA, Wood JM, McSheehy PM. et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009; 15 (05) 1612-1622
    CrossrefPubMedGoogle Scholar
  • 40 Naruse T, Yanamoto S, Yamada S. et al. Anti-tumor effect of the mammalian target of rapamycin inhibitor everolimus in oral squamous cell carcinoma. Pathol Oncol Res 2015; 21 (03) 765-773
    CrossrefPubMedGoogle Scholar
  • 41 Mak MP, William Jr WN. Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention. Oral Oncol 2014; 50 (10) 918-923
    CrossrefPubMedGoogle Scholar
  • 42 Normanno N, Bianco C, Strizzi L. et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 2005; 6 (03) 243-257
    CrossrefPubMedGoogle Scholar
  • 43 Sari S, Andayani TM, Endarti D, Widayati K. Cost-effectiveness analysis of afatinib versus gefitinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation in Indonesia: observational studies with retrospectives. Research J Pharmacy Technology 2022; 15 (04) 1598-2
    CrossrefGoogle Scholar
  • 44 Goerner M, Seiwert TY, Sudhoff H. Molecular targeted therapies in head and neck cancer–an update of recent developments-. Head Neck Oncol 2010; 2 (01) 8-9
    CrossrefPubMedGoogle Scholar
  • 45 Dhairyasheel G, Adhikrao Y, Varsha G. Design and development of solid self-microemulsifying drug delivery of gefitinib. Asian J Pharm Tech 2018; 8 (04) 193-199
    CrossrefGoogle Scholar
  • 46 Aldoss IT, Ganti AK. Targeted therapy for squamous cell carcinoma of the head and neck. J Egypt Natl Canc Inst 2009; 21 (02) 157-166
    PubMedGoogle Scholar
  • 47 Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 2005; 5 (08) 1085-1093
    CrossrefPubMedGoogle Scholar
  • 48 Vermorken JB, Mesia R, Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359 (11) 1116-1127
    CrossrefPubMedGoogle Scholar
  • 49 Naruse T, Yanamoto S, Matsushita Y. et al. Cetuximab for the treatment of locally advanced and recurrent/metastatic oral cancer: an investigation of distant metastasis. Mol Clin Oncol 2016; 5 (02) 246-252
    CrossrefPubMedGoogle Scholar
  • 50 Xu X. Short-term efficacy of nimotuzumab combined with docetaxel-cisplatin- fluorouracil in the treatment of advanced oral cancer. Electronic J General Stomatology 2016; 3 (11) 79-80
    Google Scholar
  • 51 Hamakawa H, Nakashiro K, Sumida T. et al. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 2008; 30 (06) 800-809
    CrossrefPubMedGoogle Scholar
  • 52 Shintani S, Li C, Mihara M, Nakashiro K, Hamakawa H. Gefitinib (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells. Cancer Lett 2003; 201 (02) 149-155
    CrossrefPubMedGoogle Scholar
  • 53 Kumar VK, Raju NA, Begum S, Rao JS, Satyanarayana T. The estimation of gefitinib in tablet dosage forms by RP-HPLC. Research J Pharm Tech 2009; 2 (02) 341-343
    Google Scholar
  • 54 Moral M, Paramio JM. Akt pathway as a target for therapeutic intervention in HNSCC. Histol Histopathol 2008; 23 (10) 1269-1278
    PubMedGoogle Scholar
  • 55 Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22 (01) 77-85
    CrossrefPubMedGoogle Scholar
  • 56 Fumagalli I, Dugue D, Bibault JE. et al. Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines. OncoTargets Ther 2015; 8: 335-345
    CrossrefPubMedGoogle Scholar
  • 57 Weiss JM, Bagley S, Hwang WT. et al. Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma. Cancer 2016; 122 (15) 2350-2355
    CrossrefPubMedGoogle Scholar
  • 58 Cunha SI, Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011; 117 (26) 6999-7006
    CrossrefPubMedGoogle Scholar
  • 59 Hawinkels LJ, de Vinuesa AG, Paauwe M. et al. Activin receptor-like kinase 1 ligand trap reduces microvascular density and improves chemotherapy efficiency to various solid tumors. Clin Cancer Res 2016; 22 (01) 96-106
    CrossrefPubMedGoogle Scholar
  • 60 Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ. et al. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer 2009; 100 (09) 1379-1384
    CrossrefPubMedGoogle Scholar
  • 61 Wang C, Ren M. Progress in endostatin and its application in cancer therapy. Int J Genet 2010; 33 (05) 298-302
    Google Scholar
  • 62 Li L, Cao L. Clinical effect analysis of endostatin combined with chemotherapy in the treatment of multiple advanced malignant tumors, electron. J Clin Med Lit 2017; 4 (95) 18632-18634
    Google Scholar